Deqi Pharmaceutical-B (06996) announced interim results with net profit of 216 million yuan, turning a year-on-year loss into a profit

According to the Zhitong Finance App, Deqi Pharmaceutical-B (06996) announced the interim results for the six months ended June 30, 2026. The group's revenue was 513 million yuan, up 864.75% year on year; net profit was 216 million yuan, which turned a year-on-year loss into a profit; and profit per share was 0.34 yuan.

In March 2026, the company entered into a licensing agreement with UCB (a global biopharmaceutical company (stock code: UCB) listed on the Euronext Brussels Exchange (Euronext Brussels)). According to this, Deqi will grant UCB an exclusive global license to further develop, produce and commercialize the ATG-201 (CD19 x CD3 T-cell connector (TCE)). In return, Deqi received a down payment of 60 million dollars, and after meeting certain conditions, he will receive an additional 20 million US dollars in recent milestone payments, and will be eligible for up to about 1.1 billion US dollars in future milestone payments based on successful development and commercialization, as well as tiered royalties calculated based on future net sales.